Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600120021) titled 'Remimazolam's Effect on Sleep Disorders in Patients with Pituitary Tumors: A Single-center, Randomized, Double-blind Controlled Trial Protocol' on March 8.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Huashan Hospital Affiliated to Fudan University
Condition:
Sleep disorders in patients with pituitary tumors
Intervention:
Trial Group:Anesthesia induction: Remimazolam besylate 0.2-0.3 mg/kg, Sufentanil 0.3-0.5 µg/kg, Rocuronium 0.6-0.9 mg/kg
Anesthesia maintenance: Continuous infusion of remimazolam 0.1-0.3 mg/h
Control Group:Anesthesia induction: Propofol 1.5-2.5 mg/kg, Su...